Refine
H-BRS Bibliography
- yes (3)
Departments, institutes and facilities
Document Type
- Article (3)
Year of publication
- 2017 (3) (remove)
Language
- English (3)
Keywords
- CIK cells (1)
- cancer treatment (1)
- cytokine-induced killer (CIK) cells (1)
- cytokine-induced killer cells (1)
- histone deacetylase inhibitors (1)
- immunotherapy (1)
- major histocompatibility complex class I polypeptide-related sequence A (MICA) (1)
- member D (NKG2D) (1)
- multiple myeloma (1)
- multiple myeloma (MM) (1)
- natural killer group 2 (1)
Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4-5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment.